Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

(CSE: DTR )

0.4300 +0.0500 (+13.16%)
Streaming Delayed Price Updated: 9:30 AM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DTR

Prof. Sayan Basu to Present Pivotal Results of Largest Dry Eye Syndrome Clinical Study with DiagnosTear's TeaRx(TM) Product at ARVO 2025
TeaRx™ is the first diagnostic solution to provide a comprehensive assessment of Dry Eye Syndrome, which potentially reduces empirical treatment practices and undesired costs to the healthcare system 
Via TheNewswire.com
DiagnosTear Technologies Inc. Grants Stock Options
February 5, 2025 – TheNewswire - Vancouver, BC – DiagnosTear Technologies Inc. (CSE:DTR) ("DiagnosTear" or the “Company”) announces that today it has granted 3,380,095 incentive stock options to... 
Via TheNewswire.com
DiagnosTear Advances Production for First 100,000 TeaRx(TM) Red Eye Diagnostic Devices
Vancouver, Canada – TheNewswire - February 4, 2025 – DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the “Company”), a leader in developing cutting-edge point-of-care eye diagnostic... 
Via TheNewswire.com
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.